Full-year 2021 Financial Guidance Reaffirmed
- Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan
- Regulatory Actions in Europe for Vosoritide and Valoctocogene Roxaparvovec Tracking as Expected; BioMarin Anticipates CHMP Opinion in June for Vosoritide and June Re-submission of MAA for Valoctocogene Roxaparvovec
- FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 Results
https://finance.yahoo.com/news/biomarin-announces-first-quarter-2021-200300584.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.